An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients with Acute Promyelocytic Leukemia Read more
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered In Combination With Reduced-Intensity Chemotherapy, In Patients With Actively Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Read more
A Phase 2, Open Label, Single Arm, Multi‐Center Study To Assess The Efficacy And Safety Of BST‐236 As A Single Agent In Adults Unfit For Intensive Chemotherapy With Relapsed Or Refractory Acute Myeloid Leukemia Or Higher-Risk Myelodysplastic Syndrome? Read more
Phase II RARA(+) Actively Diagnosed/Untreated AML Study With Venetoclax/Azacitidine And SY-1425 With The Primary Objective To Characterize The Safety And Tolerability Of The Triplet Regimen. Read more
A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naïve Subjects Who Require Red Blood Cell Transfusions Read more
A Phase 1b Dose Escalation Study Of Lemzoparlimab (TJ011133) In Combination With Azacitidine And/Or Venetoclax In Subjects With Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS Azacitidine And/Or Venetoclax In Subjects With Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS Read more
Connect MDS And AML: The Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukemia (AML) Disease Registry Read more
A Phase 1/2 Study Of Alx148 In Combination With Azacitidine In Patients With Higher Risk Mds Read more
